Acceder

Farmas USA

135K respuestas
Farmas USA
86 suscriptores
Farmas USA
Página
7.808 / 17.004
#62457

Re: Farmas USA

Sí, con tantos sucesos y pseudo-noticias en contra, sean o no fundados, sean o no veraces, se hace muy difícil luchar. Cornudos y apaleados... :(

AMRN

#62459

Re: Farmas USA

Pero no querías ponerte corto? Eso es amor incondicional, y lo demás son tonterías! jeje

Suerte con ellas!

AMRN

#62461

Re: Farmas USA

Bien hecho.

Si no pasó nada raro,van a ser buenos,la compañia insisto en que pinta muy bien,pasa que queda un mundo por recorrer,pero oye,que aprovechar esta ola te sale bien fijo,y las que te quedan por surfear!.

Amrn

#62462

Re: Farmas USA

My Fellow Cellceutix Shareholders,

We are pleased to inform you that Cellceutix Chief Medical Officer Dr. Daniel Jorgensen’s presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) on our completed Phase 2b trial comparing Brilacidin to daptomycin in the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) has become public on the ECCMID website. Shareholders are encouraged to view the presentation at: http://eccmidlive.org/resources/a-randomized-double-blind-study-comparing-single-dose-and-short-course-brilacidin-to-daptomycin-in-the-treatment-of-acute-bacterial-skin-skin-structure-infections-absssi--2

We’d also like to point shareholders to an informative video created by BioCentury titled, “The Future of Cancer Therapies.” We found particularly interesting the discussion with the FDA’s Dr. Richard Pazdur and Dr. Amy McKee on the approval of the PARP inhibitor Lynparza to treat advanced ovarian cancer associated with defective BRCA genes. We are encouraged in the development of our anti-cancer drug Kevetrin by the FDA’s willingness to incentivize the regulatory processes for hard-to-treat diseases like ovarian cancer. The video is available at: http://www.biocenturytv.com/currentshows2 bcpid=4179652879001&bclid=4178277878001

Sincerely,

The Cellceutix Team

#62463

Re: Farmas USA

jeje Sí, fue por eso de los 1,94$. Bueno, de cara a la decisión del juez puede ser buen plan. Salen los earnings mejor de lo esperado, se dispara, y luego ya te puedes poner corto junto al juez :)

AMRN

#62464

Re: Farmas USA

GILD

Los resultados se presentarán este jueves 30/4 al cierre de la sesión.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2015 financial results will be released on Thursday, April 30, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the first quarter 2015 and provide a general business update.

Te puede interesar...

- No hay entradas a destacar -

- No hay entradas a destacar -

Brokers destacados